Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib versus best available therapy in myelofibrosis with thrombocytopenia
ACTRN12614000740695Phase 3Recruiting
- Sponsor
- CTI BioPharma Corp.
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of pacritinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF) (3 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Spleen volume response and symptom response for pooled pacritinib arms versus best available therapy. Started Jul 2014; status: recruiting.
02
Drugs
pacritinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on ACTRN12614000740695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000740695.